VRBCF Stock Chart & Stats
$372.76
--
Market closed
$372.76
--
Day’s Range― - ―
52-Week Range$340.60 - $473.86
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$3.03B
Enterprise Value$3.16K
Total Cash (Recent Filing)$122.50M
Total Debt (Recent Filing)$288.83M
Price to Earnings (P/E)17.3
Beta0.57
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.43%
Share Statistics
EPS (TTM)17.97
Shares Outstanding8,390,660
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio5.39
Price to Book (P/B)2.67
Price to Sales (P/S)2.05
P/FCF Ratio29.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$419.04Price Target Upside12.42% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)23.79
Revenue Forecast (FY)$1.80B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And ProfitabilityAccelerating revenue alongside consistently solid margins indicates broadening demand and durable operating performance. Maintaining roughly 10% net margins gives Virbac resources to support research, product development, commercial expansion, and resilience across the next several quarters.
Conservative Balance SheetLow-to-moderate leverage and a growing equity base provide financial flexibility for investment and withstand business volatility. Strong mid-teens returns on equity also indicate that Virbac is using its capital productively while maintaining a comparatively conservative funding profile.
Diversified Animal Health PlatformA broad portfolio spanning species, product categories, and geographies diversifies revenue sources within the animal-health market. Its integrated R&D, manufacturing, and distribution model can support product control, repeat demand, and margin capture rather than relying solely on distribution.
Bears Say
Moderate Cash ConversionHealthy reported profits are not converting fully into free cash flow, and the decline from 2024 signals weaker cash quality. Persistent working-capital or investment needs could increase year-to-year cash volatility and limit the funds available for debt reduction, acquisitions, or shareholder returns.
Limited Margin ExpansionStable profitability is positive, but the absence of margin expansion limits operating leverage from revenue growth. Recent EBIT and EBITDA compression, together with historical gross-margin volatility, suggests earnings growth may remain sensitive to product mix, costs, or other operating factors.
Higher Leverage Versus Prior YearsVirbac remains conservatively financed, but rising leverage reduces the balance-sheet flexibility it previously enjoyed. If debt continues increasing faster than equity or earnings, interest commitments and financing needs could constrain investment choices and reduce resilience during weaker trading periods.
Virbac SA News
VRBCF FAQ
What was Virbac SA’s price range in the past 12 months?
Virbac SA lowest stock price was $340.60 and its highest was $473.86 in the past 12 months.
What is Virbac SA’s market cap?
Virbac SA’s market cap is $3.03B.
When is Virbac SA’s upcoming earnings report date?
Virbac SA’s upcoming earnings report date is Sep 17, 2026 which is in 4 days.
How were Virbac SA’s earnings last quarter?
Virbac SA released its earnings results on Mar 17, 2026. The company reported $9.485 earnings per share for the quarter.
Is Virbac SA overvalued?
According to Wall Street analysts Virbac SA’s price is currently Undervalued.
Does Virbac SA pay dividends?
Virbac SA pays a Annually dividend of $1.66 which represents an annual dividend yield of 0.43%. See more information on Virbac SA dividends here
What is Virbac SA’s EPS estimate?
Virbac SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virbac SA have?
Virbac SA has 8,390,660 shares outstanding.
What happened to Virbac SA’s price movement after its last earnings report?
Virbac SA reported an EPS of $9.485 in its last earnings report. Following the earnings report the stock price went up 1.98%.
Which hedge fund is a major shareholder of Virbac SA?
Currently, no hedge funds are holding shares in VRBCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Virbac SA
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.
VRBCF Stock 12 Month Forecast
Average Price Target
$419.04
▲(12.42% Upside)
Technical Analysis
Ownership Overview
―
Insiders
6.97% Mutual Funds
― Other Institutional Investors
89.74% Public Companies and
Individual Investors